相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tertiary lymphoid structures in cancer
Ton N. Schumacher et al.
SCIENCE (2022)
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Justina X. Caushi et al.
NATURE (2021)
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
Giacomo Oliveira et al.
NATURE (2021)
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Paula Voabil et al.
NATURE MEDICINE (2021)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC
Lingzhi Hong et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma (vol 577, pg 561, 2020)
Rita Cabrita et al.
NATURE (2020)
Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
Gabriel S. Krigsfeld et al.
JOURNAL OF CLINICAL PATHOLOGY (2020)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
Mohamed Amgad et al.
NPJ BREAST CANCER (2020)
CD8+ T cell states in human cancer: insights from single-cell analysis
Anne M. Van der Leun et al.
NATURE REVIEWS CANCER (2020)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma (vol 577, 561, 2020)
Rita Cabrita et al.
NATURE (2020)
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study
Anne-Marie Boothman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Sonja Althammer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Juan C. Osorio et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautes-Fridman et al.
NATURE REVIEWS CANCER (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma
Viktor H. Koelzer et al.
HISTOPATHOLOGY (2018)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen et al.
NATURE MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
Keith E. Steele et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
Jean-David Fumet et al.
BRITISH JOURNAL OF CANCER (2018)
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies
Cory Batenchuk et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer
Laurence Buisseret et al.
MODERN PATHOLOGY (2017)
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy
Thomas J. Gniadek et al.
MODERN PATHOLOGY (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention
Catherine Sautes-Fridman et al.
FRONTIERS IN IMMUNOLOGY (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
